Your session is about to expire
← Back to Search
This trial is testing a new drug for people with glioblastoma or non-small cell lung cancer who have disease progression following standard of care.
- Epidermal Growth Factor Receptor Mutations
- Solid Tumors
- Non-Small Cell Lung Cancer
- Lung Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You have a serious heart condition.You have a condition with symptoms or imaging that suggest the spread of cancer to the covering of the brain and spinal cord.You are expected to live for at least three more months.You have a gastrointestinal disorder that is not well managed.You have cancer that has spread to your brain or spine and is causing urgent symptoms that need immediate medical attention.You meet the requirements for having the medical condition that the study is testing.Your body's organs and bone marrow are working properly.
- Group 1: Dose Escalation Cohorts - Monotherapy
- Group 2: Disease-Specific Dose Expansion Cohorts - Monotherapy
- Group 3: Disease-Specific Dose Expansion Cohort - Combination Treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How widely dispersed is the current trial?
"The recruitment for this study is underway at 10 separate sites, including those located in Greenville, New York, and Nashville. Due to the necessity of follow-up visits it may be beneficial to choose a location close by when enrolling."
Has the FDA sanctioned BDTX-1535 Monotherapy?
"Due to the dearth of evidence for safety and efficacy, BDTX-1535 Monotherapy has been rated a 1 on our assessment scale. This is in line with it being a Phase 1 trial."
Are there any openings left for participants in this experiment?
"This medical endeavour, which was initially posted on March 31st 2022, is still recruiting participants as indicated by clinicaltrials.gov with the most recent update being released November 9th 2022."
Share this study with friends